NASDAQ: EXAS 104.41
-2.30 -2.15% Minimum 20 min delay
4:00 PM ET on Sep 16, 2019
Volume: 1,208,288
NASDAQ: EXAS 104.41
-2.30 -2.15% Minimum 20 min delay
4:00 PM ET on Sep 16, 2019
Volume: 1,208,288

Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard

02/21/2019
- Fourth quarter revenue increased 64 percent to $143.0 million
- Fourth quarter Cologuard test volume increased 66 percent to 292,000 completed tests, expanding estimated market share to 4.1 percent
- Nearly 15,000 healthcare providers ordered their first Cologuard test during the fourth quarter, and approximately 147,000 have ordered since the test was launched

MADISON, Wis., Feb. 21, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $454.5 million and completed approximately 934,000 Cologuard tests during the year ended Dec. 31, 2018. Full-year 2018 revenue and Cologuard test volume grew 71 percent and 64 percent from 2017, respectively.

Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP)

During the fourth quarter of 2018, the company generated revenue of $143.0 million and completed approximately 292,000 Cologuard tests. Fourth-quarter 2018 revenue and test volume grew 64 percent and 66 percent from the same period of 2017, respectively.

"The Exact Sciences team made tremendous progress in 2018, and we look forward to helping more people get screened for colorectal cancer in 2019 through our partnership with Pfizer," said Kevin Conroy, chairman and CEO of Exact Sciences. "Our team continues working hard to advance our pipeline of liquid biopsy tests to deliver additional life-changing innovations in early cancer detection."

Fourth-Quarter 2018 Financial Results

For the three-month period ended December, 31 2018, as compared to the same period of 2017 (where applicable):

  • Revenue was $143.0 million, an increase of 64 percent, and test volume was 292,000, an increase of 66 percent
  • Average Cologuard recognized revenue per test was $486, a decrease of 2 percent
  • Average Cologuard cost per test was $129, an improvement of 4 percent
  • Gross margin was 73 percent, an increase of 20 basis points
  • Operating expenses were $154.1 million, an increase of 77 percent
  • Net loss was $54.0 million or $0.44 per share, compared to $21.8 million or $0.18 per share
  • Non-cash interest expense related to convertible debt was $8.4 million, or $0.07 per share
  • Cash utilization was $61.0 million including $17.9 million related to the Biomatrica acquisition, compared to $37.8 million
  • Cash, cash equivalents and marketable securities were $1.1 billion at the end of the quarter
  • Nearly 15,000 healthcare providers ordered their first Cologuard test during the fourth quarter, and approximately 147,000 have ordered since the test was launched

2019 Outlook

  • The company anticipates revenue of $710-$730 million during 2019.

The company's guidance for revenue is a forward-looking statement. It is subject to various risks and uncertainties that could cause the company's actual results to differ materially from the anticipated targets. There can be no assurance the company will meet these financial projections. See the cautionary information about forward-looking statements in the "Safe Harbor Statement" section of this press release.

Fourth-Quarter Conference Call & Webcast

Company management will host a conference call and webcast on Thursday, Feb. 21, 2019 at 5 p.m. ET to discuss fourth-quarter 2018 results. The webcast will be available at www.exactsciences.com. Domestic callers should dial 877-201-0168 and international callers should dial +1-647-788-4901.

An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally. The access code for the replay of the call is 7363029. The webcast, conference call and replay are open to all interested parties.

About Cologuard

Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the American Cancer Society's (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. Medicare and most major insurers cover Cologuard. For more information about Cologuard, visit www.cologuardtest.com. Rx Only.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payer reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our ability to effectively utilize strategic partnerships, such as our Promotion Agreement with Pfizer, Inc., and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815

Media Contact:
J.P. Fielder
Exact Sciences Corp.
jpfielder@exactsciences.com
608-210-5220

EXACT SCIENCES CORPORATION

Selected Unaudited Financial Information

Condensed Consolidated Statements of Operations

(Amounts in thousands, except per share data)












Three Months Ended


Twelve Months Ended



December 31,


December 31,



2018


2017


2018


2017










Laboratory service revenue


$  142,981


$               87,406


$   454,462


$           265,989










Cost of sales


38,160


23,495


117,982


79,196

Gross margin


104,821


63,911


336,480


186,793










Operating expenses:









Research and development


20,932


12,675


68,210


42,139

General and administrative


56,432


33,598


178,293


109,040

Sales and marketing


76,773


40,627


249,448


153,924

Total operating expenses


154,137


86,900


495,951


305,103

Loss from operations


(49,316)


(22,989)


(159,471)


(118,310)










Other income (expense)









Investment income


6,321


1,320


21,203


3,932

Interest expense


(10,972)


(51)


(36,789)


(206)

Total other income


(4,651)


1,269


(15,586)


3,726










Net loss before tax


(53,967)


(21,720)


(175,057)


(114,584)










Income tax benefit


(7)


(44)


(92)


187










Net loss


$  (53,974)


$              (21,764)


$  (175,149)


$          (114,397)










Net loss per share - basic and diluted


$      (0.44)


$                 (0.18)


$       (1.43)


$               (0.99)










Weighted average common shares outstanding - basic and diluted


122,981


119,950


122,207


115,684

 

EXACT SCIENCES CORPORATION

Selected Unaudited Financial Information

Condensed Consolidated Balance Sheets

(Amounts in thousands)








December 31,


 December 31, 



2018


2017

Assets





Cash and cash equivalents


$              160,430


$               77,491

Marketable securities


963,752


347,224

Accounts receivable, net


44,239


26,419

Inventory, net


39,148


26,027

Prepaid expenses and other current assets


20,498


10,055

Property and equipment, net


245,259


79,986

Intangibles, Net


46,281


24,205

Other long-term assets


4,415


7,153

Total assets


$           1,524,022


$              598,560






Liabilities and stockholders' equity 





Total current liabilities


$              136,590


$               68,124

Convertible notes, net


$              664,749


$                      -

Long term debt


24,073


4,269

Other long-term liabilities


9,475


5,749

Lease incentive obligation, less current portion


8,194


-

Total stockholders' equity


680,941


520,418

Total liabilities and stockholders' equity 


$           1,524,022


$              598,560

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/total-2018-revenue-increased-71-percent-to-454-million-and-934-000-people-were-screened-with-cologuard-300800024.html

SOURCE EXACT SCIENCES CORP